|
1
|
Stasch JP, Pacher P and Evgenov OV:
Soluble guanylate cyclase as an emerging therapeutic target in
cardiopulmonary disease. Circulation. 123:2263–2273. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hampl V and Herget J: Role of nitric oxide
in the pathogenesis of chronic pulmonary hypertension. Physiol Rev.
80:1337–1372. 2000.PubMed/NCBI
|
|
3
|
Evgenov OV, Ichinose F, Evgenov NV, Gnoth
MJ, Falkowski GE, Chang Y, Bloch KD and Zapol WM: Soluble guanylate
cyclase activator reverses acute pulmonary hypertension and
augments the pulmonary vasodilator response to inhaled nitric oxide
in awake lambs. Circulation. 110:2253–2259. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Egemnazarov B, Sydykov A, Schermuly RT,
Weissmann N, Stasch JP, Sarybaev AS, Seeger W, Grimminger F and
Ghofrani HA: Novel soluble guanylyl cyclase stimulator BAY 41–2272
attenuates ischemia-reperfusion-induced lung injury. Am J Physiol
Lung Cell Mol Physiol. 296:L462–L469. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ghofrani HA, Galie N, Grimminger F, Grunig
E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A,
et al: Riociguat for the treatment of pulmonary arterial
hypertension. N Engl J Med. 369:330–340. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ghofrani HA, D'Armini AM, Grimminger F,
Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR,
Fritsch A, et al: Riociguat for the treatment of chronic
thromboembolic pulmonary hypertension. N Engl J Med. 369:319–329.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lapp H, Mitrovic V, Franz N, Heuer H,
Buerke M, Wolfertz J, Mueck W, Unger S, Wensing G and Frey R:
Cinaciguat (BAY 58–2667) Improves cardiopulmonary hemodynamics in
patients with acute decompensated heart failure. Circulation.
119:2781–2788. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dumitrascu R, Weissmann N, Ghofrani HA,
Dony E, Beuerlein K, Schmidt H, Stasch JP, Gnoth MJ, Seeger W,
Grimminger F and Schermuly RT: Activation of soluble guanylate
cyclase reverses experimental pulmonary hypertension and vascular
remodeling. Circulation. 113:286–395. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Geschka S, Kretschmer A, Sharkovska Y,
Evgenov OV, Lawrenz B, Hucke A, Hocher B and Stasch JP: Soluble
guanylate cyclase stimulation prevents fibrotic tissue Remodelling
and improves survival in salt-sensitive dahl rats. PLoS One.
6:e218532011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hoeper MM and Granton J: Intensive care
unit management of patients with severe pulmonary hypertension and
right heart failure. Am J Respir Crit Care Med. 184:1114–1124.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cernacek P and Stewart DJ: Immunoreactive
endothelin in human plasma: Marked elevations in patients in
cardiogenic shock. Biochem Biophys Res Commun. 161:562–567. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sheehan F and Redington A: The right
ventricle: Anatomy, physiology and clinical imaging. Heart.
94:1510–1515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ventetuolo CE and Klinger JR: Management
of acute right ventricular failure in the intensive care unit. Ann
Am Thorac Soc. 11:811–822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guide for the Care and Use of Laboratory
Animals. 8th edition. National Academies Press; Washington, DC:
2011, PubMed/NCBI
|
|
15
|
Ventilation with lower tidal volumes as
compared with traditional tidal volumes for acute lung injury and
the acute respiratory distress syndrome. The acute respiratory
distress syndrome network. N Engl J Med. 342:1301–1308. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stasch J, Dembowsky K, Perzborn E, Stahl E
and Schramm M: Cardiovascular actions of a novel NO-independent
guanylyl cyclase stimulator, BAY 41–8543: In vivo studies. Brit J
Pharmacol. 135:344–355. 2002. View Article : Google Scholar
|
|
17
|
Dellinger RP, Levy MM, Carlet JM, Bion J,
Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale
R, et al: Surviving sepsis campaign: International guidelines for
management of severe sepsis and septic shock: 2008. Crit Care Med.
36:296–327. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cawley SM, Kolodziej S, Ichinose F,
Brouckaert P, Buys ES and Bloch KD: sGC{alpha}1 mediates the
negative inotropic effects of NO in cardiac myocytes independent of
changes in calcium handling. Am J Physiol Heart Circ Physiol.
301:H157–H163. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sarkar D, Vallance P, Amirmansour C and
Harding SE: Positive inotropic effects of NO donors in isolated
guinea-pig and human cardiomyocytes independent of NO species and
cyclic nucleotides. Cardiovasc Res. 48:430–439. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zaccolo M and Movsesian MA: cAMP and cGMP
signaling cross-talk: Role of phosphodiesterases and implications
for cardiac pathophysiology. Circ Res. 100:1569–1578. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Francis SH, Busch JL, Corbin JD and Sibley
D: cGMP-dependent protein kinases and cGMP phosphodiesterases in
nitric oxide and cGMP action. Pharmacol Rev. 62:525–563. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nagendran J, Archer SL, Soliman D, Gurtu
V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB,
et al: Phosphodiesterase type 5 is highly expressed in the
hypertrophied human right ventricle, and acute inhibition of
phosphodiesterase type 5 improves contractility. Circulation.
116:238–248. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shan X, Quaile MP, Monk JK, French B,
Cappola TP and Margulies KB: Differential expression of PDE5 in
failing and nonfailing human myocardium. Circ Heart Fail. 5:79–86.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kilbourn RG, Jubran A, Gross SS, Griffith
OW, Levi R, Adams J and Lodato RF: Reversal of endotoxin-mediated
shock by NG-methyl-L-arginine, an inhibitor of nitric oxide
synthesis. Biochem Biophys Res Commun. 172:1132–1138. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stasch JP, Alonso-Alija C, Apeler H,
Dembowsky K, Feurer A, Minuth T, Perzborn E, Schramm M and Straub
A: Pharmacological actions of a novel NO-independent guanylyl
cyclase stimulator, BAY 41–8543: In vitro studies. Brit J
Pharmacol. 135:333–343. 2002. View Article : Google Scholar
|
|
26
|
Evgenov OV, Kohane DS, Bloch KD, Stasch
JP, Volpato GP, Bellas E, Evgenov NV, Buys ES, Gnoth MJ, Graveline
AR, et al: Inhaled agonists of soluble guanylate cyclase induce
selective pulmonary vasodilation. Am J Respir Crit Care Med.
176:1138–1145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Christenson J, Lavoie A, O'Connor M,
Bhorade S, Pohlman A and Hall JB: The incidence and pathogenesis of
cardiopulmonary deterioration after abrupt withdrawal of inhaled
nitric oxide. Am J Respir Crit Care Med. 161:1443–1449. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Badejo AM Jr, Nossaman VE, Pankey EA,
Bhartiya M, Kannadka CB, Murthy SN, Nossaman BD and Kadowitz PJ:
Pulmonary and systemic vasodilator responses to the soluble
guanylyl cyclase stimulator, BAY 41–8543, are modulated by nitric
oxide. Am J Physiol Heart Circ Physiol. 299:H1153–H1159. 2010.
View Article : Google Scholar : PubMed/NCBI
|
